Can Finerenone Alter Glomerular Disease Trajectory? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Can Finerenone Alter Glomerular Disease Trajectory?

A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

  • By

  • Kathryn Wighton

  • June 5, 2026

  • 4 min

Share

  • 1

    The FIND-CKD trial included 903 participants with glomerular diseases, assessing the effects of finerenone versus placebo.

  • 2

    Finerenone reduced the eGFR decline by 1.22 mL/min/1.73 m² per year after 3 months compared to placebo.

  • 3

    In the immunoglobulin A nephropathy subgroup, finerenone decreased urinary albumin-to-creatinine ratio by 47%.

  • 4

    Serious adverse events were similar between finerenone (20%) and placebo (21%) groups, with low rates of hyperkalemia.

  • 5

    The study faced limitations, including reliance on investigator-reported diagnoses and lack of biopsy confirmation for many participants.

Original Source(s)

Can Finerenone Alter Glomerular Disease Trajectory?

  • by Kathryn Wighton

  • June 5, 2026

Related Content

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

Knee sepsis may be rare across tibial fracture care

Investigators documented acute knee sepsis after both intra- and extra-articular nailing of open tibial shaft fractures.

Menopause may be underdocumented in EHRs

Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.